MX2017013358A - Métodos para tratar el cáncer. - Google Patents
Métodos para tratar el cáncer.Info
- Publication number
- MX2017013358A MX2017013358A MX2017013358A MX2017013358A MX2017013358A MX 2017013358 A MX2017013358 A MX 2017013358A MX 2017013358 A MX2017013358 A MX 2017013358A MX 2017013358 A MX2017013358 A MX 2017013358A MX 2017013358 A MX2017013358 A MX 2017013358A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- treating cancer
- capox
- folfox
- regorafenib
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Métodos que comprenden la administración y kits que comprenden al menos un compuesto de fórmula (I): y al menos una terapia contra el cáncer adicional seleccionada de entre panitumumab, cetuximab, capecitabina, CAPOX, regorafenib y FOLFOX.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562149349P | 2015-04-17 | 2015-04-17 | |
PCT/US2016/028179 WO2016168858A1 (en) | 2015-04-17 | 2016-04-18 | Methods for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017013358A true MX2017013358A (es) | 2018-08-01 |
Family
ID=55854800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017013358A MX2017013358A (es) | 2015-04-17 | 2016-04-18 | Métodos para tratar el cáncer. |
Country Status (16)
Country | Link |
---|---|
US (1) | US20180098959A1 (es) |
EP (1) | EP3283070A1 (es) |
JP (1) | JP2018511642A (es) |
KR (1) | KR20170137833A (es) |
CN (1) | CN107820426A (es) |
AU (1) | AU2016249158A1 (es) |
BR (1) | BR112017022296A2 (es) |
CA (1) | CA2983013A1 (es) |
EA (1) | EA201792286A1 (es) |
HK (1) | HK1250943A1 (es) |
IL (1) | IL255016A0 (es) |
MX (1) | MX2017013358A (es) |
PH (1) | PH12017501881A1 (es) |
SG (1) | SG11201708505WA (es) |
TW (1) | TW201709905A (es) |
WO (1) | WO2016168858A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2736563C (en) | 2007-09-10 | 2016-01-26 | Boston Biomedical, Inc. | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
JP6433085B2 (ja) | 2013-04-09 | 2018-12-05 | ボストン バイオメディカル, インコーポレイテッド | がんの処置に使用するための2−アセチルナフト[2,3−b]フラン−4,9−ジオン |
CA3045306A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
JP2020520923A (ja) | 2017-05-17 | 2020-07-16 | ボストン バイオメディカル, インコーポレイテッド | がんを処置するための方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2736563C (en) * | 2007-09-10 | 2016-01-26 | Boston Biomedical, Inc. | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
US20100297118A1 (en) * | 2007-12-27 | 2010-11-25 | Macdougall John | Therapeutic Cancer Treatments |
WO2013166618A1 (en) * | 2012-05-08 | 2013-11-14 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE |
JP6433085B2 (ja) * | 2013-04-09 | 2018-12-05 | ボストン バイオメディカル, インコーポレイテッド | がんの処置に使用するための2−アセチルナフト[2,3−b]フラン−4,9−ジオン |
-
2016
- 2016-04-18 MX MX2017013358A patent/MX2017013358A/es unknown
- 2016-04-18 SG SG11201708505WA patent/SG11201708505WA/en unknown
- 2016-04-18 KR KR1020177032742A patent/KR20170137833A/ko unknown
- 2016-04-18 WO PCT/US2016/028179 patent/WO2016168858A1/en active Application Filing
- 2016-04-18 TW TW105112095A patent/TW201709905A/zh unknown
- 2016-04-18 US US15/567,070 patent/US20180098959A1/en not_active Abandoned
- 2016-04-18 AU AU2016249158A patent/AU2016249158A1/en not_active Abandoned
- 2016-04-18 EP EP16723855.9A patent/EP3283070A1/en not_active Withdrawn
- 2016-04-18 CN CN201680032521.2A patent/CN107820426A/zh active Pending
- 2016-04-18 EA EA201792286A patent/EA201792286A1/ru unknown
- 2016-04-18 JP JP2017554375A patent/JP2018511642A/ja active Pending
- 2016-04-18 BR BR112017022296A patent/BR112017022296A2/pt not_active Application Discontinuation
- 2016-04-18 CA CA2983013A patent/CA2983013A1/en not_active Abandoned
-
2017
- 2017-10-15 IL IL255016A patent/IL255016A0/en unknown
- 2017-10-18 PH PH12017501881A patent/PH12017501881A1/en unknown
-
2018
- 2018-08-14 HK HK18110437.0A patent/HK1250943A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
SG11201708505WA (en) | 2017-11-29 |
HK1250943A1 (zh) | 2019-01-18 |
PH12017501881A1 (en) | 2018-03-05 |
BR112017022296A2 (pt) | 2018-07-10 |
US20180098959A1 (en) | 2018-04-12 |
CN107820426A (zh) | 2018-03-20 |
KR20170137833A (ko) | 2017-12-13 |
TW201709905A (zh) | 2017-03-16 |
AU2016249158A1 (en) | 2017-11-02 |
EA201792286A1 (ru) | 2018-03-30 |
JP2018511642A (ja) | 2018-04-26 |
WO2016168858A1 (en) | 2016-10-20 |
EP3283070A1 (en) | 2018-02-21 |
CA2983013A1 (en) | 2016-10-20 |
IL255016A0 (en) | 2017-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020550901A1 (en) | Macrocyclic compounds for treating disease | |
MX2018010473A (es) | Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73). | |
MY198613A (en) | Nitrobenzyl derivatives of anti-cancer agents | |
SG10201811841UA (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
MX2020012165A (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer. | |
MX2019001125A (es) | Inhibidores de cinasa macrociclica. | |
MX2016015363A (es) | Terapias de combinacion para el tratamiento de cancer. | |
MX2017000408A (es) | Compuestos antiproliferativos y métodos de uso de los mismos. | |
PH12017501879A1 (en) | Methods for treating cancer | |
NZ718190A (en) | Substituted quinazolines for inhibiting kinase activity | |
NZ629456A (en) | Methods for treating cancer using tor kinase inhibitor combination therapy | |
PH12017501881A1 (en) | Methods for treating cancer | |
AU2015267099A8 (en) | Use of eribulin in the treatment of cancer | |
WO2019035863A8 (en) | PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS | |
BR112014024017A8 (pt) | Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3 | |
WO2019090347A8 (en) | Adenosine pathway inhibitors for cancer treatment | |
EA201492187A1 (ru) | Способы лечения солидных опухолей с использованием кофермента q10 | |
MX2018006531A (es) | Agentes para el tratamiento de enfermedades asociadas con la proliferacion celular no deseada. | |
PH12017501880A1 (en) | Methods for treating cancer | |
MX2017012068A (es) | Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos. | |
MX2018001369A (es) | Combinaciones de inhibidores de tirosina quinasa de bruton y sus usos. | |
MX2016015568A (es) | Derivados de nucleosidos para el tratamiento del cancer. | |
BR112018072887A2 (pt) | método de tratamento de câncer de cérebro em um indivíduo, e utilização de um composto | |
WO2019036417A3 (en) | Inhibition of ngly1 for the treatment of cancer | |
MX356102B (es) | Compuestos y métodos para tratar leucemia. |